Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.

Dodson A, Okonji D, Assersohn L, Rigg A, Sheri A, Turner N, Smith I, Parton M, Dowsett M.

Breast Cancer Res Treat. 2018 Feb;168(1):249-258. doi: 10.1007/s10549-017-4514-z. Epub 2017 Nov 11.

2.

Hormone replacement therapy and women with premature menopause--a cancer survivorship issue.

King J, Wynne CH, Assersohn L, Jones A.

Eur J Cancer. 2011 Jul;47(11):1623-32. doi: 10.1016/j.ejca.2011.04.007. Epub 2011 May 9.

PMID:
21561765
3.

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.

Leary A, Assersohn L, Cunningham D, Norman AR, Chong G, Brown G, Ross PJ, Costello C, Higgins L, Oates J.

Cancer Chemother Pharmacol. 2009 Aug;64(3):455-62. doi: 10.1007/s00280-008-0893-5. Epub 2008 Dec 23.

PMID:
19104814
4.

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients.

O'Brien ME, Borthwick A, Rigg A, Leary A, Assersohn L, Last K, Tan S, Milan S, Tait D, Smith IE.

Br J Cancer. 2006 Dec 18;95(12):1632-6.

5.

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.

Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, Assersohn L, Sodha N, Salter J, Gusterson B, Dowsett M, Eeles R.

Cancer Lett. 2007 Mar 18;247(2):259-65. Epub 2006 Jun 14.

PMID:
16777318
6.

Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.

Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE.

Radiology. 2006 May;239(2):361-74. Epub 2006 Mar 16.

PMID:
16543585
7.

Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.

Urruticoechea A, Archer CD, Assersohn LA, Gregory RK, Verrill M, Mendes R, Walsh G, Smith IE, Johnston SR.

Br J Cancer. 2005 Feb 14;92(3):475-9.

8.

Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.

Assersohn L, Salter J, Powles TJ, A'hern R, Makris A, Gregory RK, Chang J, Dowsett M.

Breast Cancer Res Treat. 2003 Nov;82(2):113-23.

PMID:
14692655
9.

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR.

Ann Oncol. 2004 Jan;15(1):64-9.

PMID:
14679122
10.

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

Assersohn L, Norman AR, Cunningham D, Iveson T, Seymour M, Hickish T, Massey A, Prior Y, Hill ME.

Eur J Cancer. 2003 May;39(8):1121-8.

PMID:
12736112
11.

Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.

Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET.

Breast Cancer Res. 2002;4(3):R3. Epub 2002 Mar 20.

12.

A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy.

Assersohn L, Souberbielle BE, O'Brien ME, Archer CD, Mendes R, Bass R, Bromelow KV, Palmer RD, Bouilloux E, Kennard DA, Smith IE.

Clin Oncol (R Coll Radiol). 2002 Feb;14(1):23-7.

PMID:
11899903
13.

The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses.

Assersohn L, Gangi L, Zhao Y, Dowsett M, Simon R, Powles TJ, Liu ET.

Clin Cancer Res. 2002 Mar;8(3):794-801.

14.

Clinical studies of apoptosis and proliferation in breast cancer.

Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE.

Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

PMID:
10732783
15.

Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy.

Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, Chang J, Querci della Rovere U, Naziri N.

Ann Oncol. 1999 Dec;10(12):1451-5.

PMID:
10643535
16.

Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M.

J Clin Oncol. 1999 Oct;17(10):3058-63.

PMID:
10506600
17.

Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.

Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J.

Br J Cancer. 1999 Apr;79(11-12):1800-5.

Supplemental Content

Loading ...
Support Center